SGC-CLK-1

SGC-CLK-1 is an inhibitor of CDC-like kinase 1 (Clk1) and Clk2 (IC50s = 13 and 4 nM, respectively). It is selective for Clk1 and Clk2 over Clk3, Clk4, homeodomain-interacting protein kinase 1 (HIPK1), HIPK2, and serine/threonine kinase 16 (STK16, IC50s = 363, 46, 50, 42, and 49 nM, respectively). SGC-CLK-1 (1 µM) inhibits the proliferation of MDA-MB-435 breast cancer and U-118 MG glioma cells. It induces diffuse localization of Clk2 and phosphorylated serine/arginine-rich (pSR) proteins, targets of Clks, without reducing the levels of phosphorylated SR proteins in MDA-MB-435 and U-118 MG cells when used at a concentration of 500 nM. See the Structural Genomics Consortium (SGC) website for more information.Formal Name: 4-(6-methoxypyrazolo[1,5-b]pyridazin-3-yl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]-2-pyrimidinamine. CAS Number: 748142-15-6. Synonyms: CAF-170, CDC-like Kinase 1. Molecular Formula: C19H15F3N6O2. Formula Weight: 416.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Sparingly soluble: 1-10 mg/ml. SMILES: FC(F)(C1=CC(NC2=NC=CC(C3=C(C=CC(OC)=N4)N4N=C3)=N2)=CC(OC)=C1)F. InChi Code: InChI=1S/C19H15F3N6O2/c1-29-13-8-11(19(20,21)22)7-12(9-13)25-18-23-6-5-15(26-18)14-10-24-28-16(14)3-4-17(27-28)30-2/h3-10H,1-2H3,(H,23,25,26). InChi Key: GJYVLTPTDBQQCY-UHFFFAOYSA-N.